Featured Press Releases

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Regemat 3D to Distribute VitroInk® Bioinks in Europe: A Strategic Move for Advanced Bioprinting Solutions

Regemat 3D to Distribute VitroInk® Bioinks in Europe: A Strategic Move for Advanced Bioprinting Solutions

  • 21 Feb 2025

TheWell Bioscience, a leading biotech company specializing in xeno-free biofunctional hydrogels...

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®

Brainomix

Brainomix's AI-Powered e-Lung, Developed with AstraZeneca, Improves Identification of Lung Fibrosis Patients at Risk

IFF Pharma Solutions launches METHOCEL™ HPMC with low nitrite content to mitigate nitrosamine risks

IFF Pharma Solutions launches METHOCEL™ HPMC with low nitrite content to mitigate nitrosamine risks

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.